Y-mabs announces initiation of submission of omburtamab rolling biologics license application to fda

Y-mabs announces initiation of submission of omburtamab rolling biologics license application to the fda.y-mabs therapeutics, - expects to present results of phase 2 studies 101 and 03-133 later this year.
YMAB Ratings Summary
YMAB Quant Ranking